APPLICATION
NDA214275
TYPE
NDA
ORIGINAL APPROVAL
2021-07-29
LATEST ACTION
2026-05-23
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
UPTRAVI · ReferencePrescription
SELEXIPAG 1.8MG/VIAL · POWDER · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.